NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announced it entered into a securities purchase agreement with institutional accredited investors ("Purchasers") in connection with a private placement to issue secured senior convertible debentures (the "Debentures") and two series of new warrants exercisable for NovaBay common stock (the "Warrants") exerciseable at $1.30 per share. NovaBay intends to use the net proceeds received from the offering for working capital and general corporate purposes.
Ladenburg Thalmann & Co., Inc. acted as exclusive placement agent for the Offering.
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and skincare products. NovaBay's leading product, Avenova® Antimicrobial Lid & Lash Solution, is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is also available directly to eyecare consumers through online distribution channels such as Amazon. DERMAdoctor® offers more than 30 OTC dermatologist-developed skincare products through the DERMAdoctor website, well-known traditional and digital beauty retailers, and international distributors. For more information, visit https://novabay.com/.
The information and material presented is provided for informational purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or buy any securities mentioned herein.